Navigation Links
China Sky One Medical, Inc. Obtains Production License Renewal for Sumei Slim Patch
Date:6/22/2009

HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it obtained a renewal of its license for the production its proprietary Sumei Slim Patch from Heilongjiang Provincial FDA, which will be effective through April of 2013. Categorized as a medical device, the document number for the renewed SFDA approval of the Sumei Slim Patch is 2640029.

The Sumei Slim Patch is one of the Company's best selling products, accounting for 22% of total revenues in 2008. It is marketed and sold as a natural way to lose weight and has been shown to be 76.9% effective in clinical trials. Active ingredients in the Sumei Slim Patch include plant volatile oils and saponins, a class of chemical compounds found to regulate and restrain excessive secretion of certain hormones in order to foster weight loss. The Sumei Slim Patch, which employs the theories of Traditional Chinese Medicine (TCM), has become a widely accepted weight loss product in China, Southeastern Asia, and in other countries and regions of the world. There are quite a few reputable pharmaceutical companies and beauty product companies that have been marketing similar weight loss products in patch form, such as the "Perfect Slim Patch" from L'Oreal. Since the beginning of 2008, China Sky One Medical has sold over 7 million units of its Slim Patch around the world.

"Clinical trials conducted by the Heilongjiang Province Hospital have shown that the Sumei Slim Patch is a highly effective medical device that is a safe and reliable method for treating obesity based on the World Health Organization (WHO) definition of that term," said Mr. Yan-Qing
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email: